GlobalData on MSN26d
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trialUS-based biopharmaceutical company Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial ...
(RTTNews) - Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton's ...
Gil Blum has given his Buy rating due to a combination of factors surrounding the promising data for Nurix Therapeutics’ NX-5948 in the treatment of relapsed/refractory Waldenstrom’s ...
近日，Nurix Therapeutics（“Nurix”）在第 12 届华氏巨球蛋白血症国际研讨会 (IWWM-12) 上公布旗下NX-5948的 1a/1b 期临床试验积极数据。NX-5948是一种布鲁顿 ...
Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom ...
Nurix Therapeutics公司日前公布了在研口服、可穿越血脑屏障的布鲁顿氏酪氨酸激酶（BTK）蛋白降解剂NX-5948，在治疗复发/难治性华氏巨球蛋白血症（WM）患者的1a/1b期临床试验中的最新数据。数据显示，接受NX-5948治疗的患者中客观缓解率达到77.8%，其中两例患者已接受治疗超过1年。 基于截至2024年10月10日的数据，在9例可评估应答的患者中，7例患者（77.8%）出 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback